T2	intervention 78 93	zoledronic acid
T3	condition 116 125	bone loss
T5	total-participants 535 538	551
T6	eligibility 539 658	postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment
T7	intervention-participants 694 697	274
T8	control 711 718	delayed
T9	control-participants 720 723	277
T11	iv-bin-percent 1011 1016	10.2%
T12	cv-bin-percent 1053 1058	41.2%
T13	outcome 1249 1288	grade 1/2 elevated creatinine and fever
T14	outcome 1539 1551	Osteoporosis
T15	iv-bin-abs 1607 1608	2
T16	cv-bin-abs 1612 1613	8
T17	outcome 1705 1719	Bone fractures
T18	iv-bin-abs 1732 1734	24
T19	cv-bin-abs 1780 1782	25
T1	outcome 962 1006	lumbar spine bone mineral density at 5 years
T4	outcome 1513 1523	arthralgia
T10	outcome 1528 1537	back pain
